June 24, 2010

NASDAQ OMX (NASDAQ:NDAQ) announced that Oasmia Pharmaceutical AB (OASM), a Small Cap company within the Biotech sector, today starts trading of its shares on the main market of NASDAQ OMX Stockholm. Oasmia is the twelfth company to list on NASDAQ OMX in Europe in 2010.

Oasmia Pharmaceutical AB is based in Sweden and was founded in 1999. Oasmia develops a new generation of pharmaceuticals with the emphasis on human and veterinary oncology, with a vision to improve treatments of severe diseases. Learn more about Oasmia »

Follow Oasmia's share information »

Weine Nejdemo CFO of Oasmia Pharmaceutical AB, is welcomed to NASDAQ OMX Nordic by Jenny Rosberg Senior Vice President, NASDAQ OMX. 

Annette Ljungmark, Head of Accounting and Human Resources,  tolls the bell together with Weine Nejdemo.


Weine Nejdemo recevies a frame with the first closed deal.
  Oasmia celebrating the first day of listing at NASDAQ OMX Nordic.


CEO of Oasmia Pharmaceutical AB, Julian Aleksov.